Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc.’s chief financial officer, Brett Sandercock, has reported the sale of 1,000 shares of ResMed common stock on 2 January 2026 at a price of $241.75 per share, in a transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. Following the sale, Sandercock continues to hold 86,495 ResMed shares directly, indicating that the trade represents a small portion of his overall stake and appears to be part of a structured diversification or liquidity program rather than a change in senior management’s overall alignment with shareholders.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a global medical technology company specializing in devices and software for the treatment of sleep-disordered breathing and other chronic respiratory conditions, including CPAP machines, masks and cloud-connected solutions. The company focuses on improving patient outcomes in sleep and respiratory care markets, serving both healthcare providers and home-care channels worldwide.
Average Trading Volume: 1,171,191
Technical Sentiment Signal: Buy
Current Market Cap: A$53.07B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.